retatrutide triple agonist glp-1 gip glucagon phase 2 trial obesity First 3 data, a Triumph of Science! Retatrutide's mechanisms of action. |
Description
Patients report forgetting to eat, feeling full after a few bites, and losing interest in food entirely
Consider whether you're prepared to either continue medication long-term or develop habits that support maintenance once you reach your goals
L.van LeeuwenN.TavendaleR.BennettA
Now, they are building on their out-of-this-world research efforts to help tackle the obesity epidemic
